Your browser is no longer supported. Please, upgrade your browser.
Settings
CELC [NASD]
Celcuity Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own32.70% Shs Outstand10.28M Perf Week19.81%
Market Cap326.09M Forward P/E- EPS next Y-1.97 Insider Trans0.00% Shs Float5.04M Perf Month71.62%
Income-9.50M PEG- EPS next Q-0.20 Inst Own15.80% Short Float0.27% Perf Quarter120.26%
Sales- P/S- EPS this Y-28.20% Inst Trans1.37% Short Ratio0.03 Perf Half Y362.14%
Book/sh1.14 P/B22.70 EPS next Y-93.10% ROA-60.20% Target Price30.00 Perf Year385.55%
Cash/sh- P/C- EPS next 5Y28.00% ROE-64.40% 52W Range4.03 - 28.10 Perf YTD182.53%
Dividend- P/FCF- EPS past 5Y-30.80% ROI- 52W High-7.89% Beta1.46
Dividend %- Quick Ratio10.30 Sales past 5Y- Gross Margin- 52W Low542.18% ATR1.89
Employees30 Current Ratio10.30 Sales Q/Q- Oper. Margin- RSI (14)75.10 Volatility13.70% 7.99%
OptionableNo Debt/Eq0.00 EPS Q/Q-40.60% Profit Margin- Rel Volume0.24 Prev Close26.55
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume393.79K Price25.88
Recom2.00 SMA2048.23% SMA5062.12% SMA200164.79% Volume92,842 Change-2.52%
Jan-28-21Reiterated H.C. Wainwright Buy $14 → $18
Dec-24-20Reiterated H.C. Wainwright Buy $11 → $14
May-11-20Resumed Craig Hallum Buy
Nov-20-18Initiated H.C. Wainwright Buy $36
Apr-16-21 03:54PM  
Apr-15-21 08:58AM  
Apr-12-21 04:00PM  
09:37AM  
06:59AM  
Apr-10-21 05:13AM  
Apr-09-21 04:30PM  
06:37AM  
Apr-08-21 04:05PM  
04:02PM  
Apr-06-21 02:41AM  
Mar-18-21 08:38AM  
Mar-17-21 07:43AM  
Mar-16-21 04:00PM  
Mar-01-21 03:30PM  
Feb-24-21 02:02PM  
07:30AM  
Feb-22-21 08:00AM  
Feb-16-21 04:00PM  
02:30PM  
Feb-01-21 01:00PM  
Jan-28-21 08:03AM  
Jan-27-21 05:31PM  
Jan-19-21 02:32PM  
Jan-06-21 01:09AM  
Dec-23-20 07:00AM  
Nov-09-20 04:00PM  
02:30PM  
Oct-26-20 03:15PM  
Oct-04-20 09:30AM  
09:30AM  
Aug-27-20 09:45AM  
Aug-10-20 04:00PM  
Jul-24-20 04:45PM  
Jul-01-20 05:30PM  
Jun-22-20 07:00PM  
May-07-20 04:00PM  
Apr-23-20 04:40PM  
Apr-07-20 09:23AM  
Mar-12-20 04:00PM  
02:30PM  
Feb-27-20 04:15PM  
Dec-12-19 11:07AM  
Dec-11-19 07:25PM  
08:34AM  
Dec-05-19 10:24AM  
Nov-07-19 04:01PM  
Nov-01-19 09:00AM  
Oct-28-19 11:28AM  
Oct-24-19 03:31PM  
Sep-24-19 08:50AM  
Sep-11-19 11:37AM  
Sep-10-19 09:01AM  
07:59AM  
Sep-09-19 09:37AM  
Aug-19-19 05:55PM  
09:00AM  
Aug-08-19 04:00PM  
Jul-25-19 03:34PM  
Jun-27-19 09:00AM  
May-20-19 02:36PM  
May-13-19 09:00AM  
May-07-19 04:01PM  
02:30PM  
Apr-29-19 10:50AM  
Apr-23-19 01:48PM  
Apr-12-19 08:50AM  
Apr-10-19 08:45AM  
Apr-04-19 08:33AM  
Mar-07-19 08:58AM  
Mar-05-19 08:48AM  
Feb-26-19 09:20PM  
04:01PM  
Feb-14-19 05:12PM  
Dec-25-18 03:00PM  
Dec-11-18 08:10AM  
Dec-07-18 06:33PM  
Nov-13-18 04:00PM  
Oct-31-18 08:00AM  
Oct-30-18 04:56PM  
Oct-19-18 07:45AM  
Oct-16-18 05:51PM  
Aug-09-18 04:00PM  
02:30PM  
Aug-02-18 04:31PM  
May-14-18 04:00PM  
May-02-18 12:28PM  
Mar-19-18 07:33AM  
Mar-15-18 04:00PM  
Mar-02-18 04:00PM  
Jan-19-18 07:30AM  
Nov-13-17 07:00AM  
Nov-02-17 01:08PM  
Oct-31-17 09:15PM  
Sep-24-17 09:57AM  
Sep-22-17 04:05PM  
Sep-20-17 06:00AM  
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.